Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02907177) involved 136 people with multiple sclerosis (MS), split into two groups of 68. One group received a combination of two medicines — ponesimod and dimethyl fumarate (DMF) — while the other group received a dummy (placebo) treatment alongside DMF. The trial was measuring things like how often MS relapses (sudden worsening of symptoms) occurred, whether disability progressed over time, and what unwanted medical events (called adverse events) participants experienced. Notably, the data shows that zero participants in either group completed the study, and all 136 were recorded as "not completed," though the reasons for this were not detailed in the reported data. The reported data shows that the ponesimod-plus-DMF group had an average of 0.237 confirmed relapses per year, compared to 0.187 in the placebo-plus-DMF group. For disability worsening measured over 96 weeks (roughly two years), 18.7% of participants in the ponesimod-plus-DMF group showed a confirmed increase in disability scores, compared to 11.9% in the placebo-plus-DMF group. The reported data also shows that 33.6% of participants in the ponesimod-plus-DMF group experienced a confirmed relapse over 96 weeks, compared to 25.7% in the placebo-plus-DMF group. Regarding unwanted medical events, 48 out of 67 treated participants in the ponesimod-plus-DMF group and 53 out of 68 in the placebo-plus-DMF group were reported to have experienced at least one adverse event. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 40700861) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Multiple Sclerosis Trial, Terminated
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You must be willing to sign a consent form before any study procedures begin.
- Women who could become pregnant must have a negative pregnancy test and use reliable birth control during the study.
- You must have been diagnosed with a relapsing form of multiple sclerosis (MS) — either relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS) that still has relapses — based on specific diagnostic guidelines from 2010.
- You must have been taking a medication called DMF (dimethyl fumarate) for at least 6 months before the screening appointment.
- Your MS must still be showing signs of activity after at least 3 months of taking DMF.
- You must be able to walk (with or without aid) and score between 0 and 6.0 on a standard MS disability scale called the EDSS.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- Women who are pregnant, breastfeeding, or planning to become pregnant during the study.
- People whose MS has been progressive from the very beginning (called primary progressive MS or progressive relapsing MS).
- People who have had an MS relapse that started within the 30 days before their initial disability assessment.
- Anyone whose personal circumstances or health conditions might prevent them from fully participating in the study, as judged by the study doctor.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial contact details on record
Principal Investigator: Tatiana Scherz, MD, PhD, Actelion
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 1 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Annualized Confirmed Relapse Rate (ARR)
Other options
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.